Separate the parts of the bill
Ask for a written quote for the care being proposed. Put the visit, ongoing service, medicine and tests on separate lines. Ask whether delivery is included.
In a small group of online weight-care offers reviewed September 26, 2026, medicine charges were separate from membership fees.
Those advertised offers do not set a price for a local clinic or for a different treatment.
The visit
Is the assessment charged separately? What would I have to pay if the assessment leads to no prescription?
Ongoing care
Is there a membership or renewal fee? What does it include?
The medicine
Is its price part of the quote? What amount of treatment does that price cover?
Tests and delivery
Which costs are extra? Who bills them, and when?
Ask the plan about your case
Take the exact medicine name and the reason for treatment to the insurance plan. Ask for the amount you would pay, not just whether the plan lists the medicine.
For Medicare drug coverage, the condition being treated matters, as of September 26, 2026.
Coverage may be available when a medicine treats an accepted condition apart from weight loss; the plan’s own rules still apply.
A plan’s agreement to pay before care proceeds is called prior authorization; its list of medicines is called a formulary.
Put a quoted price in context
The temporary Medicare GLP-1 Bridge helps pay for selected weight-loss medicines for some people who have Medicare drug insurance.
GLP-1 medicines mimic a hormone’s action; this signal in your body helps regulate hunger as well as blood sugar.
The terms checked September 26, 2026 set a $50 payment per monthly supply of a listed medicine for eligible people.
The program terms checked September 26, 2026 name July 1, 2026 for its start, while December 31, 2027 is the listed finish.
Paying $50 each month for a full year would mean $600 for the medicine alone.
These payments are excluded when calculating your annual spending limit for medicines under normal Medicare drug coverage.
The Bridge provides no extra discount for people on low incomes.
Under terms checked September 26, 2026, qualifying depends on your weight and health when treatment began, your Medicare plan and the exact medicine; the program is for adults.
Under terms checked September 26, 2026, people with type 2 diabetes are outside the Bridge; their treatment falls under normal Medicare drug coverage.
Under those terms, a 2026 payment for a GLP-1 medicine by your normal Medicare drug plan prevents Bridge use for that year.
The listed products, as of September 26, 2026, are semaglutide (Wegovy) tablets or injections, tirzepatide (Zepbound) in the KwikPen injection pen, and orforglipron (Foundayo) tablets.
Zepbound vials and other pens are excluded from this program under those terms.
Ask the person prescribing and your Medicare plan to check the full health and plan requirements in the link below before counting on this price. Ask separately about visit and test charges.
Read the Medicare program’s eligibility termsRead beyond the opening offer
Ask what the price becomes when the opening offer ends, how long you must commit and what cancellation involves. Keep the reply with the quote.
Opening-price offers for semaglutide (Ozempic, Wegovy) had terms running through December 31, 2026, when checked September 26, 2026.
Savings cards for tirzepatide (Mounjaro, Zepbound) listed the same end date.
The printed terms promise no price beyond those dates, so the amount charged afterward remains unknown.
Ask which end date applies to your quote and what you would pay after it.